Relationship Between Prostate-Specific Antigen Levels And Metabolic Syndrome In Patients With Benign Prostatic Hyperplasia And Prostate Cancer

Rustamov U.M; Azimova S.B

Authors

Rustamov U.M Andijan State Medical Institute, 170100, Uzbekistan, Andijan, Atabekova st.1
Azimova S.B Tashkent State Medical University, 100109 Tashkent, Uzbekistan, 2 Farobiy Street

Keywords:

prostate-specific antigen, metabolic syndrome, benign prostatic, dyslipidemia, prostate volume

Abstract

Prostate-specific antigen (PSA) is the most widely used biomarker for the diagnosis, risk assessment, and clinical monitoring of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Nevertheless, serum PSA concentrations are influenced not only by pathological changes in the prostate gland but also by systemic metabolic abnormalities. Metabolic syndrome, characterized by central obesity, impaired glucose metabolism, dyslipidemia, and arterial hypertension, has been increasingly recognized as an important modifier of prostate physiology through its effects on chronic inflammation, insulin resistance, oxidative stress, and hormonal imbalance. These metabolic disturbances may alter PSA secretion and reduce the diagnostic accuracy of PSA-based screening, thereby complicating the early detection and clinical evaluation of prostate diseases. However, the relationship between serum PSA levels and metabolic syndrome in patients with BPH and PCa remains incompletely understood. The present study aimed to evaluate the association between serum prostate-specific antigen levels and metabolic syndrome in patients with benign prostatic hyperplasia and prostate cancer by analyzing clinical, anthropometric, and biochemical characteristics. The study included patients diagnosed with BPH, patients with histologically confirmed prostate cancer, and an age-matched healthy control group. Clinical evaluation comprised body mass index, waist circumference, systolic and diastolic blood pressure, fasting plasma glucose, serum triglycerides, high-density lipoprotein cholesterol, prostate volume measured by transrectal ultrasonography, and serum PSA concentration. Comparative statistical analyses were performed to determine the relationship between metabolic syndrome components and PSA levels in different study groups.

References

European Association of Urology, EAU Guidelines on Prostate Cancer 2025. Arnhem, The Netherlands: European Association of Urology, 2025.

European Association of Urology, EAU Guidelines on Management of Non-neurogenic Male Lower Urinary Tract Symptoms, Including Benign Prostatic Obstruction 2025. Arnhem, The Netherlands: European Association of Urology, 2025.

H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians, vol. 75, no. 1, pp. 15–48, 2025.

N. Mottet, P. Cornford, R. C. N. van den Bergh et al., “EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer,” European Urology, vol. 87, no. 2, pp. 123–170, 2025.

K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the Metabolic Syndrome: A Joint Interim Statement of International Organizations,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009.

M. G. Saklayen, “The Global Epidemic of the Metabolic Syndrome,” Current Hypertension Reports, vol. 20, no. 2, p. 12, 2018.

S. M. Grundy, “Metabolic Syndrome Update,” Trends in Cardiovascular Medicine, vol. 34, no. 2, pp. 87–95, 2024.

A. A. Yassin, A. Haider, K. S. Haider et al., “Metabolic Syndrome, Testosterone Deficiency and Prostate Disease: Current Evidence and Clinical Implications,” World Journal of Men's Health, vol. 41, no. 2, pp. 181–197, 2023.

M. Gacci, G. Corona, L. Vignozzi et al., “Metabolic Syndrome and Benign Prostatic Enlargement: A Systematic Review and Meta-analysis,” BJU International, vol. 129, no. 5, pp. 561–572, 2022.

E. H. Kim, J. A. Larson, and G. L. Andriole, “Management of Benign Prostatic Hyperplasia,” Annual Review of Medicine, vol. 74, pp. 137–152, 2023.

S. Loeb, H. B. Carter, S. I. Berndt et al., “Complications of Prostate-specific Antigen Screening and Clinical Interpretation of PSA,” Nature Reviews Urology, vol. 19, no. 5, pp. 273–286, 2022.

P. F. Pinsky, P. C. Prorok, and B. S. Kramer, “Prostate-specific Antigen Testing: Current Status and Future Directions,” Nature Reviews Urology, vol. 18, no. 11, pp. 681–695, 2021.

C. H. Pernar, E. M. Ebot, K. M. Wilson, and L. A. Mucci, “The Epidemiology of Prostate Cancer,” Cold Spring Harbor Perspectives in Medicine, vol. 8, Art. no. a030361, 2018.

Q. Mao, Y. Lin, X. Zheng et al., “Association Between Metabolic Syndrome and Prostate Cancer Risk: An Updated Systematic Review and Meta-analysis,” Frontiers in Oncology, vol. 13, Art. no. 1184721, 2023.

F. Cantiello, A. Cicione, R. Autorino et al., “Metabolic Syndrome, Inflammation and Prostate Diseases: Current Evidence and Future Perspectives,” International Journal of Molecular Sciences, vol. 23, no. 14, Art. no. 7684, 2022.

C. De Nunzio, F. Presicce, and A. Tubaro, “Metabolic Syndrome and Lower Urinary Tract Symptoms in Men,” Current Opinion in Urology, vol. 31, no. 3, pp. 254–260, 2021.

World Health Organization, Obesity and Overweight. Geneva, Switzerland: World Health Organization, 2024.

American Diabetes Association, “Standards of Care in Diabetes—2025,” Diabetes Care, vol. 48, Suppl. 1, pp. S1–S350, 2025.

National Cholesterol Education Program, Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Updated Recommendations, 2023.

U. M. Rustamov et al., “Clinical and Biochemical Characteristics of Prostate Diseases in Patients with Metabolic Syndrome,” Andijan State Medical Institute Research Collection, 2025.